首页 | 本学科首页   官方微博 | 高级检索  
     


Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised,double-blind,placebo-controlled trial
Authors:Sinead Delany-Moretlwe  Carl Lombard  Deborah Baron  Linda-Gail Bekker  Busi Nkala  Khatija Ahmed  Modulakgotla Sebe  William Brumskine  Maposhane Nchabeleng  Thesla Palanee-Philips  Julius Ntshangase  Sidney Sibiya  Emilee Smith  Ravindre Panchia  Landon Myer  Jill L Schwartz  Mark Marzinke  Lynn Morris  Helen Rees
Affiliation:1. Wits RHI, University of the Witwatersrand, Johannesburg, South Africa;2. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa;3. MATCH, University of the Witwatersrand, Johannesburg, South Africa;4. Biostatistics Unit, Cape Town, South Africa;5. South African Medical Research Council, Cape Town, South Africa;6. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa;g. Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa;h. Setshaba Research Centre, Soshanguve, South Africa;i. Aurum Institute, Johannesburg, South Africa;j. Mecru Clinical Research Unit, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa;k. Qhakaza Mbokodo Research Centre, Ladysmith, South Africa;l. CONRAD, Eastern Virginia Medical School, Arlington, VA, USA;m. Johns Hopkins University School of Medicine, Baltimore, MD, USA;n. National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa;o. Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Abstract:
Keywords:Correspondence to: Dr Sinead Delany-Moretlwe   Wits RHI   University of the Witwatersrand   Johannesburg 2001   South Africa
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号